Product Description
Raxibacumab (ABthrax) is a human IgG1 monoclonal antibody against Bacillus anthracis protective antigen. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/20068396/)
Mechanisms of Action: Protective Antigen Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: United States
Approved Indications: Meningitis | Anthrax | Meningitis, Bacterial
Known Adverse Events: Pain Unspecified | Pruritus
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|